BioCryst to Present at Upcoming Investor Conferences
May 31 2019 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
that the company will present at the Jefferies 2019 Healthcare
Conference in New York on Wednesday, June 5, 2019 at 10:30 a.m. ET
and the JMP Securities Life Sciences Conference in New York on
Wednesday, June 19, 2019 at 3:00 p.m. ET.
Links to a live audio webcast and replay of
these presentations may be accessed in the Investors section of
BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst discovers novel, oral small-molecule medicines that treat
rare diseases in which significant unmet medical needs exist and an
enzyme plays a key role in the biological pathway of the disease.
BioCryst has several ongoing development programs including
BCX7353, an oral treatment for hereditary angioedema; BCX9930, an
oral Factor D inhibitor for the treatment of complement-mediated
diseases; galidesivir, a potential treatment for Marburg virus
disease and Yellow Fever, and a preclinical program to develop oral
ALK-2 inhibitors for the treatment of fibrodysplasia ossificans
progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase
inhibitor for the treatment of influenza, is BioCryst's first
approved product and has received regulatory approval in the U.S.,
Canada, Australia, Japan, Taiwan, Korea and the European Union.
Post-marketing commitments for RAPIVAB are ongoing. For more
information, please visit the Company's website at
www.BioCryst.com.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024